United States-based Bristol-Myers Squibb has received approval from the US Food and Drug Administration (FDA) for a four-week dosing schedule for the company's Opdivo cancer drug, it was reported yesterday.
The regulator approved the product label update offering flexible flat-dosing options every two weeks (240 mg) or every four weeks (480 mg). The product, which is a programmed death-1 (PD-1) inhibitor, was earlier approved as a two-week dosing schedule for dosage strength of 240mg for the treatment of various cancers including melanoma, non–small cell lung cancer, and renal cell carcinoma. The US FDA has also approved the product for a shorter 30-minute infusion for all of its approved indications.
The company stated that it is likely to submit dosing schedule updates for an additional approved indication to the regulator in the future.
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer